CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. It also operates approximately 140 plasma collection centers. In addition, this segment conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and developsinfluenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+61-3-93891911
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$8.27 billion
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
CSL (ASX:CSL) Frequently Asked Questions
What is CSL's stock symbol?
CSL trades on the ASX under the ticker symbol "CSL."
How often does CSL pay dividends? What is the dividend yield for CSL?
CSL announced a Interim dividend on Thursday, February 14th. Investors of record on Friday, April 12th will be given a dividend of 1.203 per share on Friday, April 12th. This represents a yield of 0.64%. The ex-dividend date is Wednesday, March 13th. View CSL's Dividend History.
Has CSL been receiving favorable news coverage?
News coverage about CSL stock has been trending neutral on Sunday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. CSL earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
Who are some of CSL's key competitors?
Some companies that are related to CSL include Shire (SHP), Moderna Inc (NASDAQ) (MRNA), Cronos Group (CRON), BTG (BTG), MorphoSys (MOR), MorphoSys (MOR), Abcam (ABC), Genus (GNS), Concordia International (CXR), Clinuvel Pharmaceuticals (CUV), Mesoblast (MSB), Resverlogix (RVX), Polynovo (PNV), Theratechnologies (TH) and Emerald Health Therapeutics (EMH).
What other stocks do shareholders of CSL own?
Who are CSL's key executives?
CSL's management team includes the folowing people:
- Mr. Paul R. Perreault, MD, CEO & Exec. Director (Age 62)
- Mr. David Mark Lamont ACA, BCom, Chief Financial Officer (Age 53)
- Dr. Robert Andrew Cuthbertson, Chief Scientific Officer & Director of R&D and Director (Age 64)
- Mr. Gregory Boss BS(Hons), J.D., Exec. VP of Legal & Group Gen. Counsel (Age 58)
- Ms. Elizabeth Walker, Exec. VP & Chief HR Officer (Age 49)
What is CSL's stock price today?
One share of CSL stock can currently be purchased for approximately A$190.51.
How big of a company is CSL?
CSL has a market capitalization of $86.32 billion and generates $8.27 billion in revenue each year.
What is CSL's official website?
How can I contact CSL?
CSL's mailing address is 45 Poplar Road,, Parkville, MELBOURNE, VIC 3052, Australia. The company can be reached via phone at +61-3-93891911.
MarketBeat Community Rating for CSL (ASX CSL)
MarketBeat's community ratings are surveys of what our community members think about CSL and other stocks. Vote "Outperform" if you believe CSL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSL will underperform the S&P 500 over the long term. You may vote once every thirty days.
